Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management

Date: December 15, 2013
Pages: 130
Price:
US$ 3,500.00
License [?]:
Publisher: GBI Research
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P071FE2977EEN
Leaflet:

Download PDF Leaflet

Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management
Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management

Summary

GBI Research has released the pharma report “Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management”. The Parkinson’s Disease (PD) market is dominated by symptomatic treatments targeting functional impairment in PD. Levodopa has remained the gold standard treatment for almost 40 years and has significantly improved patient quality of life. There is currently there is a huge unmet need for disease-modifying treatments that slow progression or have neuroprotective properties. Over the 2012–2019 forecast period, the PD market is anticipated to decline from $3.4 billion in 2012 to $2.9 billion in 2019, as a consequence of upcoming patent expirations of high-profile products such as Azilect, Stalevo and Comtan. Although a few market entrants are anticipated to enter the market over the forecast period, they are not expected to offset the impact of generic erosion. Despite their superior profiles over existing treatments, these new products are not expected to command a premium price as they will be competing against generic products. The current PD pipeline reflects a shift of focus to long-term PD management, marked by the development of key pipeline candidates targeting levodopa-associated motor complications. These products will have the potential to change the future treatment algorithm as side effects of dopaminergic therapies become more manageable.

Scope
  • A brief introduction to PD, including pathogenesis, disease staging, diagnosis and treatment algorithms
  • In-depth analysis of the drugs available for the treatment of PD, covering their safety, efficacy, treatment patterns, and strengths/weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy
  • Comprehensive review of the pipeline for PD therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period, on the basis of phase distribution, molecule type and molecular target
  • Additional in-depth analysis of pipeline drug clinical trials by Phase, molecule type, trial size, trial duration, and program failure rate analyses for each molecule type and mechanism of action
  • Multi-scenario market forecast data to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain
  • Discussion of the drivers of and barriers to market growth
  • Discussion of the licensing and co-development deals landscape in PD, by stage of development, molecule type and mechanism of action, as well as analysis both licensing and co-development deals by year, and network maps of licensing and co-development deals
Reasons to buy
  • Understand the different levels of PD therapy from early-stage to advanced
  • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
  • Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for PD therapeutics
  • Observe the trends in clinical trial duration and size amongst clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for PD therapeutics
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the PD therapeutics market
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Overview
2.2 Epidemiology
2.3 Etiology
  2.3.1 Loss of Dopaminergic Neurons
  2.3.2 Genetic Factors
  2.3.3 Exposure to Environmental Toxins
2.4 Pathophysiology
  2.4.1 Pathophysiological Changes in Basal Ganglia in Parkinson’s Disease
  2.4.2 Pathophysiological Changes Involved in the Rise of Motor Complications in Parkinson’s Disease
2.5 Symptoms
2.6 Co-morbidities and Complications
2.7 Diagnosis
  2.7.1 Classification
2.8 Prognosis and Disease Staging
2.9 Treatment Options
  2.9.1 Pharmacological Treatment
  2.9.2 Non-pharmacological Treatments
  2.9.3 Treatment Algorithm

3 MARKETED PRODUCTS

3.1 Therapeutic Landscape
  3.1.1 Dopamine Replacement Therapies
  3.1.2 MAO-B inhibitors
  3.1.3 Dopamine Agonists
  3.1.4 COMT Inhibitors
  3.1.5 Nouriast (istradefylline) - Kyowa Hakko Kirin
  3.1.6 Exelon (rivastigmine tartrate) - Novartis AG
  3.1.7 Symmetrel (amantadine hydrochloride) - Alliance Pharma Plc
  3.1.8 Other drugs targeting non-motor symptoms of PD
3.2 Comparative Efficacy and Safety
3.3 Unmet Need

4 PIPELINE FOR PARKINSON’S DISEASE

4.1 Overall Pipeline
4.2 Molecular Targets in Parkinson’s Disease Pipeline
4.3 Clinical Trials
  4.3.1 Failure Rate of Developmental Pipeline
  4.3.2 Clinical Trial Sizes
  4.3.3 Clinical Trial Duration
  4.3.4 Summary of Clinical Trial Cost and Risk Analyses
4.4 Promising Candidates in Pipeline
  4.4.1 Rytary (carbidopa, levodopa) - Impax Laboratories, Inc.
  4.4.2 Safinamide - Newron Pharmaceuticals S.p.A
  4.4.3 Pimavanserin - Acadia Pharmaceuticals Inc.
  4.4.4 Tozadenant - Biotie Therapies
  4.4.5 Mavoglurant - Novartis AG
  4.4.6 Dipraglurant - Addex Therapeutics
4.5 Heat Map of Safety and Efficacy for Parkinson’s Disease Pipeline and Marketed Products

5 MARKET FORECAST TO 2019

5.1 Geographical Markets
  5.1.1 Global Market
  5.1.2 North America
  5.1.3 Top Five Countries of Europe
  5.1.4 Japan
5.2 Drivers and Barriers
  5.2.1 Drivers
  5.2.2 Barriers

6 DEALS AND STRATEGIC CONSOLIDATIONS

6.1 Major Co-development Deals
  6.1.1 Newron Pharmaceuticals S.p.A. Enter Agreement with Zambon Company S.p.A.
  6.1.2 QR Pharma, Inc. Enter Research Agreement with Massachusetts General Hospital
  6.1.3 Ceregene, Inc. Enter Agreement with Genzyme Corporation
6.2 Major Licensing Deals
  6.2.1 Biotie Therapies Corp. Enter Worldwide Agreement with UCB Group
  6.2.2 Ono Pharmaceutical Co., Ltd. Enter Agreement with Bial - Portela & Ca, S.A
  6.2.3 Domain Therapeutics S.A. Enter Agreement with Prexton Therapeutics
  6.2.4 Newron Pharmaceuticals S.p.A. Enter Agreement with Zambon Company S.p.A.
  6.2.5 Oncodesign SA Enter Agreement with Ipsen S.A.
  6.2.6 Cephalon, Inc. Enter Licensing Agreement with Mesoblast Limited
  6.2.7 Shire Pharmaceutical Group Plc Enter Agreement with Heptares Therapeutics Ltd.

7 APPENDIX

7.1 All Pipeline Products, by Phase
7.2 Sources
7.3 Market Definition
7.4 Abbreviations
7.5 Research Methodology
  7.5.1 Coverage
  7.5.2 Secondary Research
7.6 Therapeutic Landscape
7.7 Epidemiology-Based Forecasting
7.8 Market Size by Geography
7.9 Geographical Landscape
7.10 Pipeline Analysis
7.11 Competitive Landscape
  7.11.1 Expert Panel Validation
7.12 Contact Us
7.13 Disclaimer

LIST OF TABLES

Table 1: Definition of the Stages of Disability in Hoehn and Yahr Scale
Table 2: Evaluation of Disability by UPDRS
Table 3: Definition of the Stages of Disability in Hoehn and Yahr Scale
Table 4: Evaluation of Disability by UPDRS
Table 5: All Pipeline Products by Phase, Discovery
Table 6: All Pipeline Products by Phase, Preclinical
Table 7: All Pipeline Products by Phase, IND/CTA Filed and Phase I
Table 8: All Pipeline Products by Phase, Phase II
Table 9: All Pipeline Products by Phase, Phase III and Pre-registration
Table 10: Parkinson’s Disease, Global, Market Forecast, 2012-2019
Table 11: Parkinson’s Disease, US, Market Forecast, 2012-2019
Table 12: Parkinson’s Disease, Canada, Market Forecast, 2012-2019
Table 13: Parkinson’s Disease, UK, Market Forecast, 2012-2019
Table 14: Parkinson’s Disease, France, Market Forecast, 2012-2019
Table 15: Parkinson’s Disease, Germany, Market Forecast, 2012-2019
Table 16: Parkinson’s Disease, Italy, Market Forecast, 2012-201
Table 17: Parkinson’s Disease, Spain, Market Forecast, 2012-2019
Table 18: Parkinson’s Disease, Japan, Market Forecast, 2012-2019

LIST OF FIGURES

Figure 1: Indirect and Direct Pathway in Basal Ganglia
Figure 2: Treatment Algorithm of Parkinson’s Disease
Figure 3: Treatment Algorithm of Advanced Parkinson’s Disease
Figure 4: Parkinson’s Disease Market, Global, Annual Sales of Madopar ($m), 2008-2012
Figure 5: Parkinson’s Disease Market, Global, Annual Sales of Stalevo and Comtan ($m), 2005-2012
Figure 6: Parkinson’s Disease Market, Global, Annual Sales of Azilect ($m), 2006-2012
Figure 7: Parkinson’s Disease Market, Global, Annual Sales of Requip ($m), 2001-2012
Figure 8: Parkinson’s Disease Market, Global, Annual Sales of Mirapex ($m), 2005-2010
Figure 9: Parkinson’s Disease Market, Global, Annual Sales of Neupro ($m), 2007-2012
Figure 10: Parkinson’s Disease Market, Global, Annual Sales of Apokyn ($m), 2006-2011
Figure 11: Parkinson’s Disease Market, Global, Annual Sales of Permax ($m), 2009-2012
Figure 12: Parkinson’s Disease Market, Global, Annual Sales of Exelon ($m), 2002-2012
Figure 13: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products, 2012-2019
Figure 14: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products, 2012-2019
Figure 15: Pipeline for Parkinson’s Disease, Global, 2012
Figure 16: Pipeline for Parkinson’s Disease, Global, 2012
Figure 17: Pipeline for Parkinson’s Disease, Global, Clinical Trial Failure Rates (%), 2006-2012
Figure 18: Pipeline for Parkinson’s Disease, Global, Clinical Trial Sizes (Participants), 2006-2012
Figure 19: Pipeline for Parkinson’s Disease, Global, Clinical Trial Duration (Months), 2006-2012
Figure 20: Pipeline for Parkinson’s Disease, Global, Mean Number of Clinical Trials Per Pipeline Drug, 2006-2012
Figure 21: Parkinson’s Disease Market, Global, Efficacy Heat Map for Pipeline Products, 2012-2019
Figure 22: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products, 2012-2019
Figure 23: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products, 2012-2019
Figure 24: Parkinson’s Disease Market, Global, Annual Sales ($bn), 2012-2019
Figure 25: Parkinson’s Disease Market, North America, Treatment Patterns, 2012-2019
Figure 26: Parkinson’s Disease Market, North America, Annual Cost of Therapy ($), 2012-2019
Figure 27: Parkinson’s Disease Market, North America, Market Size ($m), 2012-2019
Figure 28: Parkinson’s Disease Market, Top Five EU Countries, Treatment Patterns, 2012-2019
Figure 29: Parkinson’s Disease Market, Top Five EU Countries, Annual Cost of Therapy ($), 2012-2019
Figure 30: Parkinson’s Disease Market, Top Five EU Countries, Market Size ($m), 2012-2019
Figure 31: Parkinson’s Disease Market, Japan, Treatment Patterns and Annual Cost of Therapy ($), 2012-2019
Figure 32: Parkinson’s Disease Market, Japan, Market Size ($m), 2012-2019
Figure 33: Parkinson’s Disease Market, Global, Co-Development Deals, 2006-2013
Figure 34: Parkinson’s Disease Market, Global, Co-Development Deals, 2006-2013
Figure 35: Parkinson’s Disease Market, Global, Licensing Deals, 2006-2013
Figure 36: Parkinson’s Disease Market, Global, Licensing Deals, 2006-2013
Figure 37: Parkinson’s Disease Market, Global, Breakdown of Licensing Deals in Other Non-dopaminergic Neuromodulatory Targets, 2006-2013
Figure 38: GBI Research Market Forecasting Model

Ask Your Question

Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: